Citi analyst Samantha Semenkow downgraded MoonLake Immunotherapeutics (MLTX) to Neutral from Buy with a price target of $5, down from $72. The firm cites the “disappointing” Phase 3 VELA program data for sonelokimab in hidradenitis suppurativa for the downgrade. Citi now sees “significant” regulatory risk for the drug and points out Moonlake is now facing financing challenges.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics double-downgraded to Underperform at Wolfe Research
- MoonLake Immunotherapeutics downgraded to Underperform from Peer Perform at Wolfe Research
- MoonLake price target lowered to $12 from $108 at Clear Street
- Jefferies downgrades MoonLake Immunotherapeutics after VELA results
- MoonLake Immunotherapeutics downgraded to Hold from Buy at Jefferies